Kaiwei Si

Title: Innovations of Kaiwei Si in CRISPR Technology

Introduction

Kaiwei Si is a prominent inventor based in Guangdong, China. He is known for his significant contributions to the field of genetic engineering, particularly through his work on the CRISPR-Cas13 system. His innovative approach has the potential to revolutionize various applications in biotechnology and medicine.

Latest Patents

Kaiwei Si holds a patent for the CRISPR-Cas13 system and its applications. This invention relates to a CRISPR-Cas13 system, which includes a Cas13 protein, a fusion protein, and a guide polynucleotide. The Cas13 protein exhibits at least 90% sequence identity compared to SEQ ID NO: 1. The fusion protein consists of the Cas13 protein fused to a protein domain and/or a polypeptide tag. The guide polynucleotide features a same-direction repetition sequence and a guide sequence engineered to hybridize with target RNA. The same-direction repetition sequence has at least 70% sequence identity to any of SEQ ID NOs: 3 and 80-87. This innovative system comprises the Cas13 protein with at least 90% sequence identity to SEQ ID NO: 1, or a coding nucleic acid therefor, along with the guide polynucleotide or a coding nucleic acid therefor.

Career Highlights

Throughout his career, Kaiwei Si has worked with notable companies in the biotechnology sector, including Guangzhou Reforgene Medicine Co., Ltd. and Zhejiang Synsorbio Technology Co., Ltd. His experience in these organizations has contributed to his expertise in genetic research and development.

Collaborations

Kaiwei Si has collaborated with several professionals in his field, including Junbin Liang and Xingxiang Liang. These collaborations have further enhanced his research and innovation capabilities.

Conclusion

Kaiwei Si's work in the development of the CRISPR-Cas13 system showcases his innovative spirit and dedication to advancing genetic engineering. His contributions are poised to have a lasting impact on biotechnology and medicine.